FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI Diagnostics. Backed by Menlo.
About the role
In this role, you will be responsible for supporting high complexity process automation engineering for cancer detection via next generation sequencing. You will be troubleshooting, testing, and verifying automated scripts on liquid handlers. You will work cross-functionally with clinical laboratory scientists, tech transfer scientists, data scientists, software engineers, systems engineers, and quality.
What they're looking for
- B.S. or higher in engineering, biology, or similar field providing a strong foundation in lab automation, systems development, and science
- High level of analytical ability to solve complex technical problems
- Skilled in technical and non-technical communication
- Able to master new concepts and skills quickly, with strong attention to detail
- Comfortable working in both individual and cross-functional team settings
More about this role
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our...
Browse similar: Startup jobs · San Francisco Bay Area